Tagged with Bioscience

Singapore The latest pharma news from Singapore, including J&J Innovation’s continued investment in Singapore; Evotec’s new Singaporean venture, 65LAB; BeiGene’s cancer drug approval in the country; Novo Nordisk’s acquisition of local biotech KBP Biosciences’ late-stage investigational hypertension drug, and Crown Bioscience/JSR Life Sciences’ new manufacturing facility.   Johnson & Johnson Innovation…

India Top stories from Indian pharma including Sanofi India’s plans to demerge its healthcare businesses; Junshi Biosciences and Dr. Reddy’s anti-PD-1 monoclonal antibody partnership; Venus Remedies’ new oncology approvals; CORONA and Ferring’s maternal health agreement and Ipca Laboratories and Sun Pharma’s quality issues.   Zydus Lifesciences reports smallest profit in 14…

China A roundup of some of the biggest pharma and biotech news from China including the collaboration between Elektr and Sinopharm; Biocytogen’s partnership with Janssen and deal with Chipscreen Biosciences; China’s first personalised neoantigen-targeted cancer vaccine approval; the final green light for Sino Biopharm’s purchase of F-star, and AstraZeneca’s deal with…

Belgium A roundup of some of the biggest pharma news from Belgium including Neuraxpharm’s new Belgian affiliate, Novalis Biotech’s investment in Rarity Bioscience, Catalent’s plasmid DNA manufacturing site and a recent study on the country’s clinical trial footprint.   Neuraxpharm completes its presence in Benelux by opening an affiliate in Brussels…

Chile Korean biotech SK Bioscience, known for bringing forward the first South Korean-developed COVID-19 vaccine, is pursuing its beyond-COVID growth strategy with a new green light for its SKYCellflu vaccine. The recent approval by Chile’s Instituto de Salud Publica follows nine others and is the first in the Latin America region.…

South Korea After launching the first Korean COVID-19 vaccine, SKYCovione, SK Bioscience is preparing for its next big milestone, a US subsidiary, with the appointment of two new executives who are already securely anchored in the American life sciences ecosystem: former senior program officer in global health at the Bill & Melinda…

Korea SK Bioscience’s announcement that the first batch of its domestically developed COVID vaccine has been shipped may mark a significant milestone in South Korea’s journey towards greater vaccine self-sufficiency.   Back in October 2021, PharmaBoardroom ran through the leading Korean companies in the race to develop a homegrown vaccine against…

France Exor, led by Fiat brand heirs the Agnelli family, has signed a partnership agreement for an investment of EUR 833 million in the also family-owned French holding, Institut Mérieux, known for its diagnostic arm, BioMérieux. Under the new partnership, Exor will acquire a 10% shareholding in Institut Mérieux by way…

South Korea South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way. In 2019, the South Korean government announced a USD 1.7 billion five-year plan to fund biotech-related projects with the intention…

South Korea The latest healthcare and pharma news from South Korea, including SK Bioscience’s COVID-19 vaccine, Daewoong’s partnership with AstraZeneca Korea and UCI Therapeutics, Vivozon production halt and GC’s acquistion of US-based CDMO, BioCentriq. SK Bioscience’s COVID-19 vaccine to be tested against Omicron (Korea Biomedical Review) SK Bioscience’s has submitted a biologics…

Korea Amid global supply shortages and shipment delays for COVID-19 vaccines, South Korea has launched an ambitious 2.2 trillion won (USD 1.9 billion) investment plan to become one of the world’s five largest COVID-19 vaccine manufacturing hubs by 2025. Here, we provide a rundown of some of the key companies involved…

China Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach differs from that of its competitors, and how he plans to make the firm into “China’s Genentech.”   We want…